# Dysmenorrhea Treatment Market

> Dysmenorrhea Treatment Market Research Report Information By Product Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), By Type of Treatment (Pain Relievers, Hormonal Therapy, And Surgery), By End-User (Hospitals & Clinics And Research Centers), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Industry Therapeutics - Forecast Till 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 8.35%
- **2025:** USD 5.31 Billion
- **2035:** USD 11.83 Billion
- **Key Players:** Bayer AG, Pfizer Inc., Kenvue Inc., Haleon plc, Reckitt Benckiser Group, AbbVie Inc., Organon & Co., Sumitomo Pharma

**Report ID:** MRFR/HC/0256-CR · **Pages:** 111 · **Author:** Rahul Gotadki & Nidhi Mandole · **Last Updated:** August 26, 2026

**URL:** https://www.marketresearchfuture.com/reports/dysmenorrhea-treatment-market-727

---

## Market Summary

As per Market Research Future analysis, the Dysmenorrhea Treatment Market Size was estimated at 4.08 USD Billion in 2024. The Dysmenorrhea Treatment industry is projected to grow from 4.415 USD Billion in 2025 to 9.721 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 8.21% during the forecast period 2025 - 2035

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising diagnosed prevalence among adolescents | +1.4 | Global | Medium-term (2–4 yr) | [6] |
| OTC analgesic accessibility and Rx-to-OTC switch | +1.3 | North America, Europe | Short-term (≤2 yr) | [7] |
| Expanded hormonal prescribing for pain indication | +1.1 | North America, Europe | Medium-term (2–4 yr) | [3] |
| GnRH antagonist pipeline maturation | +0.9 | North America, Japan | Long-term (≥4 yr) | [8] |
| Telehealth and digital cycle-tracking referral flow | +0.7 | Global | Short-term (≤2 yr) | [9] |
| Public menstrual health policy and school programmes | +0.6 | Asia-Pacific, Africa | Long-term (≥4 yr) | [10] |
| Retail pharmacy expansion in emerging economies | +0.5 | Asia-Pacific, South America | Medium-term (2–4 yr) | [11] |

### Adolescent Prevalence and the Diagnosis Gap

For twenty years, treatment penetration has lagged behind prevalence data, but the gap is now narrowing. According to a 2022 BMC Women's Health cohort, 92.3% of women who presented with menstrual discomfort had non-pathological presentations, whereas 7.7% had pathological reasons. This ratio supports first-line coverage rather than referrals to specialists [[6]](https://bmcwomenshealth.biomedcentral.com). Separately, a BMJ Open study published in February 2021 revealed a prevalence of 51.5% among Ethiopian university students, demonstrating that low-income settings bear a similar burden with a fraction of the treatment expenditure [[12]](https://bmjopen.bmj.com). Within three years of their implementation, school-based screening programs in South Korea and Japan have turned about 18% of previously untreated teenagers into drugstore buyers.

### The Rx-to-OTC Switch Economics

Regulators continue to expand access to self-care. Between 2023 and 2025, naproxen sodium was made available for general sale in more European regions, and in Canada and Australia, pharmacists were granted supply authority for stronger presentations. OTC units increased 11% more quickly than prescription analgesic units across audited channels in 2024 [[7]](https://www.chpa.org). Volume follows convenience. In contrast to net realization of 30–38% on rebated prescription equivalents, brand owners keep 45–60% gross margin on shelf items.

### Hormonal Prescribing Beyond Contraception

Continuous-dose combined oral contraceptives are increasingly prescribed with pain as the primary indication rather than as a contraceptive with an incidental benefit. AbbVie disclosed that endometriosis-associated pain products contributed materially to its women's health line in 2024, and Sumitomo Pharma's acquisition of Myovant, completed in March 2023, was explicitly framed around the relugolix franchise [[3]](https://investors.abbvie.com)[[8]](https://www.sumitomo-pharma.com). Prior-authorisation friction remains the constraint; approval rates hover near 71% on first submission in US commercial plans.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Normalisation of menstrual pain and under-presentation | −1.1 | Global | Long-term (≥4 yr) | [13] |
| NSAID gastrointestinal and cardiovascular labelling | −0.8 | North America, Europe | Short-term (≤2 yr) | [14] |
| Generic erosion and tender price compression | −0.7 | Global | Medium-term (2–4 yr) | [11] |
| Hormonal therapy discontinuation from side-effect burden | −0.6 | Global | Medium-term (2–4 yr) | [15] |
| Reimbursement gaps for non-contraceptive hormonal use | −0.4 | Europe, Asia-Pacific | Long-term (≥4 yr) | [16] |

### The Under-Presentation Problem

Price barriers are not as effective at suppressing demand as cultural normalization. A median of 6.7 years has passed between the onset of symptoms and the first clinical appointment for endometriosis-related discomfort, according to survey data from twelve different countries [[13]](https://www.thelancet.com). Women use subtherapeutic OTC dosages for self-medication, decide the category is ineffective, and leave. Although manufacturers have responded by investing in direct-to-patient education, conversion economics are still unfavorable outside of high-income markets.

### Safety Labelling and Formulary Pressure

Chronic NSAID exposure is now subject to stricter regulatory monitoring. The class is now subject to warnings about cardiovascular risk and gastrointestinal bleeding, and the period of covered treatment is limited by a number of European reimbursement organizations [[14]](https://www.ema.europa.eu). A hard ceiling on per-patient revenue in the largest treatment category is the commercial result; average days of therapy per patient cannot increase, but volume can.

### Price Compression in Mature Channels

Tender-based procurement in national health systems has driven ex-manufacturer prices for mefenamic acid and ibuprofen down 22% since 2021 in audited European tenders [[11]](https://data.worldbank.org). Suppliers with single-site API dependency have exited rather than bid. The result is a thinner, more concentrated generic base — lower revenue, but paradoxically more pricing stability for those who remain.

## Opportunities

## Dysmenorrhea Treatment Market Opportunities

### Adolescent-Specific Formulations

In this area, no major manufacturer has a label specifically for teenagers. Clinical differentiation and labeling exclusivity would be established by lower-dose, faster-onset presentations with pediatric-appropriate dosing forms. Capturing brand loyalty at that entry point accumulates over a two-decade treatment horizon, since the initial symptom manifestation clusters between the ages of 13 and 17.

### Emerging-Market Retail Pharmacy Penetration

As organized retail replaces informal supply, India, Indonesia, Nigeria, and Brazil together gain about 4.1 million pharmacy-accessible female consumers each year [[11]](https://data.worldbank.org). Although unit economics are weak, a feasible margin of 8–14% net is supported by volume scale and domestically produced generics. The long-term position will be held by businesses that form joint ventures with domestic formulators instead of exporting completed items.

### Digital Adjuncts and Data-Enabled Business Models

Cycle-tracking applications now hold longitudinal symptom data on more than 250 million users worldwide. Pairing a validated digital adjunct with a prescription product creates a subscription layer atop a one-time pharmaceutical sale, and generates real-world evidence that supports payer negotiation. The Dysmenorrhea Treatment Market has barely tested this model — fewer than five commercial pairings exist today.

### Non-Hormonal Novel Mechanisms

Selective prostaglandin receptor antagonists and peripheral nerve modulators bypass both the gastrointestinal risk of NSAIDs and the systemic burden of hormonal regimens. Early-phase assets are sparse, which is precisely the argument — a first mover with a clean safety profile would face no direct comparator.

### Employer and Payer Menstrual Health Programmes

Following Spain's statutory precedent, multinational employers are building menstrual health into benefits design [[1]](https://www.boe.es). These programmes route employees toward covered clinical pathways rather than self-care, lifting per-capita treatment value. Vendors who can demonstrate absenteeism reduction in dollar terms will win these contracts.

## Future Outlook

## Dysmenorrhea Treatment Market Future Outlook

### Precision Diagnosis and Biomarker Stratification

Distinguishing pathological from non-pathological presentations currently requires laparoscopy or clinical judgement, and both are slow. Blood-based biomarker panels in late-stage validation could compress the diagnostic interval from years to weeks. If adopted at scale, the Dysmenorrhea Treatment Market gains an estimated 3.2 million newly identified specialty-eligible patients globally by 2032 — a demand shock concentrated entirely in high-value hormonal and antagonist therapies.

### Platform Economics in Women's Health

Cycle-tracking applications are consolidating into diagnostic-adjacent platforms with pharmacy fulfilment attached. Three of the five largest have added telehealth prescribing since 2023. The strategic question for manufacturers is whether to partner or be disintermediated — platforms that own the patient relationship will eventually negotiate on formulary terms, not brand terms.

### Non-Hormonal Innovation Cycle

Pipeline activity in non-hormonal mechanisms is thin but accelerating. Peripheral prostaglandin modulation and targeted nerve-signalling approaches offer an exit from the safety-ceiling problem that caps NSAID revenue per patient. First approvals are unlikely before 2030, which makes the back half of the forecast window the inflection point.

### Health Equity Reporting and Access Mandates

Institutional investors have begun scoring pharmaceutical portfolios on women's health access metrics, and the World Bank's health financing frameworks increasingly reference reproductive health service coverage as a development indicator [[19]](https://www.worldbank.org/health). Companies in the Dysmenorrhea Treatment Market that can document tiered-pricing reach in low-income geographies will find capital cheaper and public tenders easier to win. Disclosure is becoming a commercial asset, not a compliance cost.

## Segment Insights

## Dysmenorrhea Treatment Market Segmentation

Segmentation in the Dysmenorrhea Treatment Market follows three axes: what is prescribed, what condition underlies the pain, and where the product is dispensed. Value concentrates differently on each axis, which is why single-dimension analysis misleads.

### By Treatment Type

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) | 61.4% share | OTC accessibility and first-line clinical status |
| Hormonal Therapy | 10.1% CAGR (2026–2035) | Endometriosis pain management and continuous-dose prescribing |

NSAIDs remain the volume engine of the Dysmenorrhea Treatment Market and will stay there through 2035, but their revenue share erodes roughly 40 basis points annually as hormonal regimens capture the moderate-to-severe cohort. The economics are asymmetric: NSAIDs deliver enormous unit counts at low realisation, hormonal therapy delivers modest unit counts at fifteen to forty times the per-patient value.

Hormonal Therapy's momentum comes from indication expansion rather than new patients. Products originally positioned as contraceptives are now prescribed with pain as the documented primary indication, which changes both the payer conversation and the promotional strategy. Manufacturers that reposition existing assets face far lower costs than those developing new ones.

### By Type

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Primary Dysmenorrhea | USD 3.58 Billion | Broad adolescent and young-adult prevalence |
| Secondary Dysmenorrhea | 9.8% CAGR (2026–2035) | Rising endometriosis and fibroid diagnosis rates |

Primary Dysmenorrhea supplies the base. It affects the largest population, resolves adequately with inexpensive therapy, and generates predictable repeat purchasing across a fifteen-to-thirty-year patient lifespan. Growth here tracks demographics and pharmacy access, nothing more exotic.

Secondary Dysmenorrhea is where the Dysmenorrhea Treatment Market creates value. Underlying pathology justifies specialist referral, advanced imaging, and premium-priced therapy. Every improvement in endometriosis diagnostic speed converts patients out of the primary bucket and into the secondary one — a mix shift worth roughly USD 1.6 billion in incremental value by 2035 on current diagnosis trajectories [[2]](https://www.nice.org.uk).

### By Distribution Channel

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Retail Pharmacies | 54.7% share | OTC purchasing and prescription convenience |
| Hospital Pharmacies | USD 1.38 Billion | Specialist-initiated hormonal regimens |
| Online Pharmacies | 13.9% CAGR (2026–2035) | Telehealth prescribing and discretion preference |

Online dispensing is the structural story. Discretion matters disproportionately in this category, and digital channels remove the counter-conversation entirely. Regulatory tightening in Brazil and India has slowed the pace but improved the quality of surviving platforms [[17]](https://www.gov.br/anvisa).

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 38.5% share | Specialty hormonal access, employer benefits design |
| Europe | USD 1.42 Billion | Reimbursed gynaecology pathways, statutory recognition |
| Asia-Pacific | 10.4% CAGR (2026–2035) | Retail pharmacy buildout, domestic generic manufacturing |
| South America | USD 0.38 Billion | Public formulary inclusion, e-pharmacy regulation |
| Middle East & Africa | 5.2% share | Awareness programmes, urban clinic expansion |
| Total | USD 5.31 Billion | — |

Regional performance in the Dysmenorrhea Treatment Market tracks three variables: diagnosis infrastructure, prescription hormonal access, and retail pharmacy density. North America scores high on all three. Asia-Pacific scores low on the first, high on the third, and is improving fastest on the second — which is why its growth curve is the steepest in the set.

### North America

| Country | Metric | Key Driver |
| --- | --- | --- |
| US | 82.1% of region | Employer-sponsored specialty coverage |
| Canada | USD 0.24 Billion | Pharmacist prescribing authority expansion |
| Mexico | 9.6% CAGR | Organised retail pharmacy chain growth |

Commercial insurance design determines outcomes here. US plans increasingly place GnRH antagonists on specialty tiers with step-therapy requirements, which slows uptake but locks in adherence once approved. Canada's provincial expansion of pharmacist prescribing — now covering hormonal contraception in six provinces — has shifted an estimated 14% of initiations out of physician offices [[16]](https://health-products.canada.ca). Mexico's growth is a distribution story, not a clinical one.

### Europe

| Country | Metric | Key Driver |
| --- | --- | --- |
| Germany | 23.4% of region | Statutory health insurance gynaecology coverage |
| UK | USD 0.27 Billion | NICE NG73 diagnostic pathway refresh |
| France | 16.8% of region | Reimbursed specialist referral density |
| Italy | 9.9% of region | Regional formulary variation |
| Spain | 10.1% CAGR | Menstrual leave statute driving clinical presentation |
| Nordic Countries | USD 0.09 Billion | High diagnosis rates, low price realisation |
| Russia | 6.2% of region | Domestic generic substitution |
| Rest of Europe | 8.4% of region | Central European tender consolidation |

Europe's paradox is high clinical quality and low commercial value. Diagnosis rates lead the world, but tender pricing and reference-pricing linkage suppress realisation. Spain is the outlier worth watching — the June 2023 menstrual leave provision requires medical certification, which mechanically converts self-managers into diagnosed patients [[1]](https://www.boe.es). Germany's statutory funds remain the single largest payer block in the region.

### Asia-Pacific

| Country | Metric | Key Driver |
| --- | --- | --- |
| China | 31.7% of region | Hospital pharmacy volume, domestic manufacturing scale |
| India | 12.3% CAGR | Retail chain expansion, draft menstrual hygiene policy |
| Japan | USD 0.21 Billion | Established low-dose hormonal prescribing culture |
| South Korea | 8.9% of region | School screening programmes |
| ASEAN | 11.6% CAGR | E-pharmacy penetration |
| Rest of Asia-Pacific | 6.1% of region | Urban clinic density |

India carries the steepest national curve inside the Dysmenorrhea Treatment Market. The draft National Menstrual Hygiene Policy circulated in 2023 pushed menstrual health onto state health agendas, and organised pharmacy chains added roughly 9,000 outlets between 2022 and 2025 [[10]](https://mohfw.gov.in). Japan is the mature counterexample — low-dose estrogen-progestin therapy has been a standard dysmenorrhea prescription for over fifteen years, so growth there is price-driven, not penetration-driven.

### South America

| Country | Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58.3% of region | ANVISA e-pharmacy rules, public formulary listings |
| Argentina | USD 0.06 Billion | Currency-adjusted generic pricing |
| Rest of South America | 10.7% CAGR | Andean market retail formalisation |

Brazil anchors the region and sets its regulatory tone. Tightened online dispensing rules have pushed digital platforms toward licensed pharmacy partnerships rather than direct fulfilment, which slowed 2024 growth but improved channel durability [[17]](https://www.gov.br/anvisa). Argentina's numbers are distorted by currency effects; volume trends there are healthier than dollar revenue suggests.

### Middle East & Africa

| Country | Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 28.6% of region | Vision 2030 women's health clinic expansion |
| UAE | USD 0.05 Billion | Private insurance gynaecology coverage |
| South Africa | 19.2% of region | Public sector generic tender volume |
| Egypt | 11.8% CAGR | Local manufacturing cost advantage |
| Rest of MEA | 16.4% of region | Urban pharmacy access |

Gulf states are building capacity faster than demand materialises. Saudi Arabia's women's health clinic expansion under Vision 2030 has added specialist gynaecology capacity in secondary cities, but cultural reticence around menstrual complaints keeps presentation rates below regional income peers [[18]](https://www.moh.gov.sa). Egypt's advantage is manufacturing — local formulators supply both domestic and North African demand at costs that imported generics cannot match.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration is moderate. The estimated Herfindahl-Hirschman Index sits near 780, with the top five players holding a combined 38–46% of global revenue — enough to shape category pricing, not enough to control it. Fragmentation is heaviest in the generic NSAID tier, where dozens of regional formulators compete on tender price alone, and lightest in specialty hormonal therapy, where three companies effectively define the frontier. Competitive advantage in the Dysmenorrhea Treatment Market accrues to firms operating across both tiers.

| Company | Est. Revenue Share Range | Key Offerings for Dysmenorrhea Treatment Market | Strategic Positioning |
| --- | --- | --- | --- |
| Bayer AG | ~9–12% | Combined oral contraceptive franchise, naproxen sodium OTC | Dual Rx/OTC coverage, strongest women's health brand equity |
| Pfizer Inc. | ~8–11% | Ibuprofen brands, relugolix combination co-commercialisation | Broad analgesic reach plus specialty hormonal exposure |
| Kenvue Inc. | ~7–10% | Ibuprofen and acetaminophen consumer brands | Pure-play consumer health scale post-2023 separation |
| Haleon plc | ~6–9% | OTC analgesic portfolio across Europe and Asia-Pacific | Emerging-market distribution depth |
| Reckitt Benckiser Group | ~5–8% | Branded ibuprofen presentations | Premium OTC positioning, heavy consumer marketing |
| AbbVie Inc. | ~4–7% | Elagolix for endometriosis-associated pain | First-mover in oral GnRH antagonist class |
| Organon & Co. | ~4–6% | Hormonal contraceptive portfolio | Dedicated women's health focus, mid-market pricing |
| Sumitomo Pharma | ~3–5% | Relugolix combination therapy | Specialty franchise acquired via Myovant in 2023 |
| Teva Pharmaceutical Industries | ~3–5% | Generic NSAIDs and hormonal generics | Cost leadership in tender channels |
| Viatris Inc. | ~2–4% | Generic mefenamic acid, hormonal generics | Global generic footprint, API integration |
| Gedeon Richter | ~2–4% | Gynaecology-focused hormonal products | Central and Eastern European stronghold |

## Recent News & Developments

## Recent News & Developments

- Haleon plc (July 2022, full-year effects through 2023): Completed separation from GSK, creating a standalone consumer health company with a concentrated OTC analgesic portfolio and greater freedom to invest behind menstrual pain indications [[20]](https://www.haleon.com/investors).
- Sumitomo Pharma (March 2023): Closed its acquisition of Myovant Sciences, consolidating ownership of the relugolix combination franchise indicated for endometriosis-associated pain and adding a specialty women's health platform to a largely CNS-weighted portfolio [[8]](https://www.sumitomo-pharma.com).
- Kenvue Inc. (May 2023): Completed its initial public offering as the separated consumer health arm of Johnson & Johnson, placing a major ibuprofen franchise under independent capital allocation for the first time [[21]](https://investors.kenvue.com).
- Government of Spain (June 2023): Menstrual leave provisions took legal effect, requiring medical certification for incapacitating menstrual pain and formally routing affected workers into clinical pathways [[1]](https://www.boe.es).
- Government of India (2023): Circulated a draft National Menstrual Hygiene Policy elevating menstrual health across state health programmes and creating a policy basis for public-sector procurement [[10]](https://mohfw.gov.in).
- NICE, United Kingdom (November 2024): Published an updated endometriosis guideline (NG73) revising diagnostic and referral criteria, with direct consequences for how quickly patients reach prescription therapy [[2]](https://www.nice.org.uk).
- ANVISA, Brazil (2024): Tightened online pharmacy dispensing requirements, pushing digital health platforms toward licensed domestic pharmacy partnerships rather than direct cross-border fulfilment [[17]](https://www.gov.br/anvisa).
- Organon & Co. (2024–2025): Expanded its women's health commercial footprint across Asia-Pacific and Latin America, prioritising hormonal portfolio distribution in markets with growing organised retail pharmacy density [[22]](https://www.organon.com/investors).

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global market for pharmaceutical and hormonal therapies indicated for primary and secondary dysmenorrhea, spanning prescription and over-the-counter channels |
| Study Period | 2021–2035 (Historical 2021–2024; Base Year 2025; Forecast 2026–2035) |
| CAGR | 8.35% (2026–2035) |
| Market Size Checkpoints | USD 5.31 Billion (2025); USD 5.75 Billion (2026); USD 7.92 Billion (2030); USD 11.83 Billion (2035) |
| Fastest Growing Segments | Hormonal Therapy (by Treatment Type); Secondary Dysmenorrhea (by Type); Online Pharmacies (by Distribution Channel) |
| Companies Profiled | Bayer AG, Pfizer Inc., Kenvue Inc., Haleon plc, Reckitt Benckiser Group, AbbVie Inc., Organon & Co., Sumitomo Pharma, Teva Pharmaceutical Industries, Viatris Inc., Gedeon Richter |
| Valuation Currency | USD Billion (constant 2025 dollars) |

## Frequently Asked Questions

**Q: What should procurement teams weigh when tendering supply for the Dysmenorrhea Treatment Market?**
A: Prioritise suppliers with dual-site API sourcing for naproxen and ibuprofen. Lock 24-month pricing where possible, because generic price compression reverses sharply during shortage events. [Ref 11]

**Q: How do OTC and prescription channels differ in margin structure?**
A: OTC brands hold 45–60% gross margins on shelf presence and brand equity. Prescription hormonal products carry higher per-unit revenue but face payer rebates and prior-authorisation friction that compress net realisation to roughly 30–38%. [Ref 7]

**Q: Which entry route works best for new companies in the Dysmenorrhea Treatment Market?**
A: Repurposing approved molecules through abbreviated regulatory pathways cuts development timelines by three to five years. Novel chemical entities rarely justify the cost against entrenched generic competition. [Ref 25]

**Q: What integration challenges arise with digital therapeutic adjuncts?**
A: Reimbursement codes remain inconsistent across payers and clinical validation standards vary by regulator. Successful launches pair the application with an existing prescription product rather than selling it standalone. [Ref 9]

**Q: Does patent cliff exposure threaten valuations in the Dysmenorrhea Treatment Market?**
A: Only marginally. Most revenue already sits in off-patent products, so exclusivity risk concentrates in GnRH antagonists with protection running into the early 2030s. [Ref 3]

**Q: What regulatory nuance matters for cross-border e-pharmacy distribution?**
A: Hormonal products require in-market prescription validation, which blocks most cross-border models. Regulators in Brazil and India have tightened online dispensing, pushing platforms toward licensed domestic partnerships. [Ref 17]

**Q: Which emerging use case deserves the closest watch?**
A: Adolescent-specific formulations — lower-dose, faster-onset presentations designed for school-age patients. Pediatric labelling extensions offer exclusivity value alongside a defensible clinical position no incumbent currently holds. [Ref 6]


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/dysmenorrhea-treatment-market-727*